Posted by Michael Wonder on 19 Apr 2022
Health Canada approves Keytruda (pembrolizumab) for the treatment of adult patients with high risk early stage triple negative breast cancer in combination with chemotherapy as neo-adjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery
18 April 2022 - Approval Based on Data from Phase 3 KEYNOTE-522 Trial
Merck today announced that Health Canada has granted approval for Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as a treatment for adult patients with high-risk early-stage triple negative breast cancer in combination with chemotherapy as neo-adjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery.
